RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.41 Million | -1.4 Million | -2.51 Million | -765.2 Thousand | -2.78 Million | -386.09 Thousand |
| Net Income | -311.73 Thousand | -743.22 Thousand | -4.07 Million | -1.58 Million | -3 Million | -2.76 Million |
| Depreciation & Amortization | 1471.00 | 839.00 | 1148.00 | 1574.00 | 2168.00 | 2998.00 |
| Deferred income taxes | - | - | 850.2 Thousand | 175.28 Thousand | 34.03 Thousand | - |
| Stock-based compensation | 241.48 Thousand | 69.05 Thousand | 471.75 Thousand | 3397.00 | 26.27 Thousand | 326.36 Thousand |
| Change in working capital | 119.72 Thousand | 267.54 Thousand | -324.23 Thousand | 915.97 Thousand | 444.91 Thousand | 2.04 Million |
| Other non-cash items | -1.46 Million | -1 Million | 560.58 Thousand | -281.14 Thousand | -285.07 Thousand | 12.11 Thousand |
| Investing Cash Flow | - | - | - | 11.5 Thousand | -28.75 Thousand | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -28.75 Thousand | - |
| Sales/Maturities of investments | - | - | - | 11.5 Thousand | -28.75 Thousand | - |
| Other Investing Activities | - | - | - | 11.5 Thousand | 28.75 Thousand | - |
| Financing Cash Flow | 1.06 Million | 1.6 Million | 2.7 Million | 764.13 Thousand | 415.99 Thousand | 2.3 Million |
| Debt repayment | -47.2 Thousand | - | - | -47.29 Thousand | -415.99 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.01 Million | 1.6 Million | 1800.00 | 656.84 Thousand | - | 2.56 Million |
| Other Financing Activities | 1.06 Million | 1.6 Million | 2.69 Million | 154.59 Thousand | 415.99 Thousand | -256.39 Thousand |
| Accounts receivables | 44.21 Thousand | -20.92 Thousand | 2376.00 | -11.71 Thousand | 32.98 Thousand | -354.69 Thousand |
| Accounts payables | -86.88 Thousand | 321.16 Thousand | -300.89 Thousand | 858.2 Thousand | - | - |
| Inventory | - | -300.23 Thousand | 298.51 Thousand | -846.48 Thousand | - | - |
| Other working capital | 119.72 Thousand | 267.54 Thousand | -324.23 Thousand | 915.97 Thousand | 411.93 Thousand | 2.04 Million |
| Cash at beginning of period | 413.02 Thousand | 221.18 Thousand | 34.36 Thousand | 23.92 Thousand | 2.41 Million | 497.09 Thousand |
| Cash at end of period | 59.16 Thousand | 413.02 Thousand | 221.18 Thousand | 34.36 Thousand | 23.92 Thousand | 2.41 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | 1.00 | - | - |
| Net cash flow / Change in cash | -353.86 Thousand | 191.83 Thousand | 186.82 Thousand | 10.43 Thousand | -2.39 Million | 1.92 Million |
| Free Cash Flow | -1.41 Million | -1.4 Million | -2.51 Million | -765.2 Thousand | -2.78 Million | -386.09 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -187.93 Thousand | -251.83 Thousand | 2.02 Million | -311.73 Thousand | -818.6 Thousand | -558.15 Thousand |
| Depreciation & Amortization | 135.00 | 135.00 | 270.00 | 1471.00 | - | 1103.00 |
| Deferred income taxes | - | - | - | - | - | -5676.00 |
| Stock-based compensation | - | - | -23.07 Thousand | 241.48 Thousand | 234.59 Thousand | 14.97 Thousand |
| Change in working capital | 23.28 Thousand | 46.03 Thousand | 624.35 Thousand | 27.2 Thousand | -16.51 Thousand | -28.88 Thousand |
| Other non-cash items | -47.94 Thousand | 21.43 Thousand | -2.93 Million | -1.08 Million | 400.23 Thousand | 146.63 Thousand |
| Investing Cash Flow | - | 17.25 Thousand | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | 17.25 Thousand | - | - | - | - |
| Other Investing Activities | - | 17.25 Thousand | - | - | - | - |
| Financing Cash Flow | 214.76 Thousand | 100.36 Thousand | -293.56 Thousand | 1.06 Million | -1.00 | -42.49 Thousand |
| Debt repayment | -214.76 Thousand | -100.36 Thousand | -47.2 Thousand | -47.2 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -340.76 Thousand | - | - | -383.26 Thousand |
| Common Stock Issuance | - | - | - | 1.01 Million | - | -42.49 Thousand |
| Other Financing Activities | - | - | -340.76 Thousand | 1.06 Million | -1.00 | 383.26 Thousand |
| Accounts receivables | 6101.00 | -5150.00 | 65.79 Thousand | 44.21 Thousand | -5026.00 | -13.24 Thousand |
| Accounts payables | -85.46 Thousand | 29.52 Thousand | 551.49 Thousand | -86.88 Thousand | 28.42 Thousand | -135.27 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 23.28 Thousand | 21.66 Thousand | 7067.00 | 69.87 Thousand | -39.92 Thousand | 119.64 Thousand |
| Cash at beginning of period | 16.64 Thousand | 59.16 Thousand | 15.22 Thousand | 413.02 Thousand | 215.51 Thousand | 680.01 Thousand |
| Cash at end of period | 18.94 Thousand | 16.64 Thousand | 59.16 Thousand | 59.16 Thousand | 15.23 Thousand | 215.51 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 2300.00 | -42.51 Thousand | 43.93 Thousand | -353.86 Thousand | -200.28 Thousand | -464.49 Thousand |
| Free Cash Flow | -212.46 Thousand | -160.12 Thousand | 337.49 Thousand | -1.41 Million | -200.28 Thousand | -430 Thousand |
NVA
9824
QBR-A
KAJARIACER
ACI
2435